Beyond breast cancer, female-specific vulnerabilities emerge in ovarian cancers associated with BRCA mutations, where disrupted NRF2-BRCA1 interactions compromise redox defenses and reveal unique therapeutic windows, reviewed in Li et al (14). This evidence concerns the gene BRCA1 and breast cancer.